Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA)

If you have held Iovance Biotherapeutics, Inc. shares continuously since prior to May 9, 2024, you may have standing to seek corporate governance reforms at Iovance, including improvements to internal controls, transparency, and executive oversight. Shareholders who successfully pursue derivative claims on behalf of the Company may be eligible to receive an incentive award, subject to court approval.

Complaint Allegations
A recently filed securities class action complaint alleges that Iovance made materially false and/or misleading statements and/or failed to disclose material adverse facts concerning the Company’s business, operations, and prospects. Specifically, Defendants allegedly failed to disclose that: (1) the Company overstated the commercial demand and revenue potential of its lead therapy, Amtagvi; (2) operational and launch-related challenges materially impaired the product’s commercial performance; (3) internal controls and disclosure processes were inadequate; and (4) as a result, Defendants’ public statements were materially misleading and lacked a reasonable basis.